Genomics & Informatics

Korea Genome Organization (한국유전체학회)
권호 표지
DOI QR코드

DOI QR Code

Elucidating Molecular Interactions of Natural Inhibitors with HPV-16 E6 Oncoprotein through Docking Analysis

  • Kumar, Satish (Bioinformatics Centre & Biochemistry, Mahatma Gandhi Institute of Medical Sciences) ;
  • Jena, Lingaraja (Bioinformatics Centre & Biochemistry, Mahatma Gandhi Institute of Medical Sciences) ;
  • Galande, Sneha (Bioinformatics Centre & Biochemistry, Mahatma Gandhi Institute of Medical Sciences) ;
  • Daf, Sangeeta (Datta Meghe Institute of Medical Sciences (Deemed University)) ;
  • Mohod, Kanchan (Bioinformatics Centre & Biochemistry, Mahatma Gandhi Institute of Medical Sciences) ;
  • Varma, Ashok K. (Advanced Centre for Treatment, Research & Education in Cancer)
  • Received : 2014.04.25
  • Accepted : 2014.05.22
  • Published : 2014.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Human papillomavirus (HPV) infection is the leading cause of cancer mortality among women worldwide. The life-threatening infection caused by HPV demands the need for designing anticancerous drugs. In the recent years, different compounds from natural origins, such as carrageenan, curcumin, epigallocatechin gallate, indole-3-carbinol, jaceosidin, and withaferin, have been used as a hopeful source of anticancer therapy. These compounds have been shown to suppress HPV infection by different researchers. In the present study, we explored these natural inhibitors against E6 oncoprotein of high-risk HPV-16, which is known to inactivate the p53 tumor suppressor protein. A robust homology model of HPV-16 E6 was built to anticipate the interaction mechanism of E6 oncoprotein with natural inhibitory molecules using a structure-based drug designing approach. Docking analysis showed the interaction of these natural compounds with the p53-binding site of E6 protein residues 113-122 (CQKPLCPEEK) and helped the restoration of p53 functioning. Docking analysis, besides helping in silico validation of natural compounds, also helps understand molecular mechanisms of protein-ligand interactions.

Keywords

References

  1. Hoory T, Monie A, Gravitt P, Wu TC. Molecular epidemiology of human papillomavirus. J Formos Med Assoc 2008;107:198-217. https://doi.org/10.1016/S0929-6646(08)60138-2
  2. de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012;13:607-615. https://doi.org/10.1016/S1470-2045(12)70137-7
  3. Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine 2006;24 Suppl 3:S3/11-25.
  4. Guan P, Howell-Jones R, Li N, Bruni L, de Sanjose S, Franceschi S, et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer 2012;131:2349-2359. https://doi.org/10.1002/ijc.27485
  5. Chaturvedi AK. Beyond cervical cancer: burden of other HPV-related cancers among men and women. J Adolesc Health 2010;46(4 Suppl):S20-S26.
  6. Scheffner M, Munger K, Byrne JC, Howley PM. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc Natl Acad Sci U S A 1991;88:5523-5527. https://doi.org/10.1073/pnas.88.13.5523
  7. Hubbert NL, Sedman SA, Schiller JT. Human papillomavirus type 16 E6 increases the degradation rate of p53 in human keratinocytes. J Virol 1992;66:6237-6241.
  8. Bharti AC, Shukla S, Mahata S, Hedau S, Das BC. Anti-human papillomavirus therapeutics: facts & future. Indian J Med Res 2009;130:296-310.
  9. Gordaliza M. Natural products as leads to anticancer drugs. Clin Transl Oncol 2007;9:767-776. https://doi.org/10.1007/s12094-007-0138-9
  10. Buck CB, Thompson CD, Roberts JN, Muller M, Lowy DR, Schiller JT. Carrageenan is a potent inhibitor of papillomavirus infection. PLoS Pathog 2006;2:e69. https://doi.org/10.1371/journal.ppat.0020069
  11. Bava SV, Puliappadamba VT, Deepti A, Nair A, Karunagaran D, Anto RJ. Sensitization of taxol-induced apoptosis by curcumin involves down-regulation of nuclear factor-kappaB and the serine/threonine kinase Akt and is independent of tubulin polymerization. J Biol Chem 2005;280:6301-6308. https://doi.org/10.1074/jbc.M410647200
  12. Singh M, Singh N. Molecular mechanism of curcumin induced cytotoxicity in human cervical carcinoma cells. Mol Cell Biochem 2009;325:107-119. https://doi.org/10.1007/s11010-009-0025-5
  13. Sharada AC, Solomon FE, Devi PU, Udupa N, Srinivasan KK. Antitumor and radiosensitizing effects of withaferin A on mouse Ehrlich ascites carcinoma in vivo. Acta Oncol 1996;35:95-100. https://doi.org/10.3109/02841869609098486
  14. Bargagna-Mohan P, Hamza A, Kim YE, Khuan Abby Ho Y, Mor-Vaknin N, Wendschlag N, et al. The tumor inhibitor and antiangiogenic agent withaferin A targets the intermediate filament protein vimentin. Chem Biol 2007;14:623-634. https://doi.org/10.1016/j.chembiol.2007.04.010
  15. Munagala R, Kausar H, Munjal C, Gupta RC. Withaferin A induces p53-dependent apoptosis by repression of HPV oncogenes and upregulation of tumor suppressor proteins in human cervical cancer cells. Carcinogenesis 2011;32:1697-1705. https://doi.org/10.1093/carcin/bgr192
  16. Ahn WS, Yoo J, Huh SW, Kim CK, Lee JM, Namkoong SE, et al. Protective effects of green tea extracts (polyphenon E and EGCG) on human cervical lesions. Eur J Cancer Prev 2003;12:383-390. https://doi.org/10.1097/00008469-200310000-00007
  17. Qiao Y, Cao J, Xie L, Shi X. Cell growth inhibition and gene expression regulation by (-)-epigallocatechin-3-gallate in human cervical cancer cells. Arch Pharm Res 2009;32:1309-1315. https://doi.org/10.1007/s12272-009-1917-3
  18. Lee HG, Yu KA, Oh WK, Baeg TW, Oh HC, Ahn JS, et al. Inhibitory effect of jaceosidin isolated from Artemisiaargyi on the function of E6 and E7 oncoproteins of HPV 16. J Ethnopharmacol 2005;98:339-343. https://doi.org/10.1016/j.jep.2005.01.054
  19. Yuan F, Chen DZ, Liu K, Sepkovic DW, Bradlow HL, Auborn K. Anti-estrogenic activities of indole-3-carbinol in cervical cells: implication for prevention of cervical cancer. Anticancer Res 1999;19:1673-1680.
  20. Kelley LA, Sternberg MJ. Protein structure prediction on the Web: a case study using the Phyre server. Nat Protoc 2009;4:363-371. https://doi.org/10.1038/nprot.2009.2
  21. Krieger E, Joo K, Lee J, Raman S, Thompson J, Tyka M, et al. Improving physical realism, stereochemistry, and side-chain accuracy in homology modeling: four approaches that performed well in CASP8. Proteins 2009;77 Suppl 9:114-122. https://doi.org/10.1002/prot.22570
  22. Laskowski RA, MacArthur MW, Moss DS, Thornton JM. PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Crystallogr 1993;26:283-291. https://doi.org/10.1107/S0021889892009944
  23. Wiederstein M, Sippl MJ. ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Res 2007;35:W407-W410. https://doi.org/10.1093/nar/gkm290
  24. Wallner B, Elofsson A. Can correct protein models be identified? Protein Sci 2003;12:1073-1086. https://doi.org/10.1110/ps.0236803
  25. Eisenberg D, Luthy R, Bowie JU. VERIFY3D: assessment of protein models with three-dimensional profiles. Methods Enzymol 1997;277:396-404. https://doi.org/10.1016/S0076-6879(97)77022-8
  26. Colovos C, Yeates TO. Verification of protein structures: patterns of nonbonded atomic interactions. Protein Sci 1993;2:1511-1519. https://doi.org/10.1002/pro.5560020916
  27. Wang Y, Xiao J, Suzek TO, Zhang J, Wang J, Bryant SH. PubChem: a public information system for analyzing bioactivities of small molecules. Nucleic Acids Res 2009;37:W623-W633. https://doi.org/10.1093/nar/gkp456
  28. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 2009;30:2785-2791. https://doi.org/10.1002/jcc.21256
  29. Zanier K, Charbonnier S, Sidi AO, McEwen AG, Ferrario MG, Poussin-Courmontagne P, et al. Structural basis for hijacking of cellular LxxLL motifs by papillomavirus E6 oncoproteins. Science 2013;339:694-698. https://doi.org/10.1126/science.1229934
  30. Cherry JJ, Rietz A, Malinkevich A, Liu Y, Xie M, Bartolowits M, et al. Structure based identification and characterization of flavonoids that disrupt human papillomavirus-16 E6 function. PLoS One 2013;8:e84506. https://doi.org/10.1371/journal.pone.0084506
  31. Vande Pol SB, Klingelhutz AJ. Papillomavirus E6 oncoproteins. Virology 2013;445:115-137. https://doi.org/10.1016/j.virol.2013.04.026
  32. Crook T, Tidy JA, Vousden KH. Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Cell 1991;67:547-556. https://doi.org/10.1016/0092-8674(91)90529-8

Cited by

  1. Docking to Explicate Interface between Plant-Originated Inhibitors and E6 Oncogenic Protein of Highly Threatening Human Papillomavirus 18 vol.13, pp.2, 2015, https://doi.org/10.5808/GI.2015.13.2.60
  2. Molecular Probing of the HPV-16 E6 Protein Alpha Helix Binding Groove with Small Molecule Inhibitors vol.11, pp.2, 2016, https://doi.org/10.1371/journal.pone.0149845
  3. Identification of Suitable Natural Inhibitor against Influenza A (H1N1) Neuraminidase Protein by Molecular Docking vol.14, pp.3, 2016, https://doi.org/10.5808/GI.2016.14.3.96
  4. Study vol.14, pp.4, 2016, https://doi.org/10.5808/GI.2016.14.4.241
  5. Bringing Curcumin to the Clinic in Cancer Prevention: a Review of Strategies to Enhance Bioavailability and Efficacy vol.19, pp.1, 2017, https://doi.org/10.1208/s12248-016-0003-2
  6. Computational Molecular Docking and X-ray Crystallographic Studies of Catechins in New Drug Design Strategies vol.23, pp.8, 2018, https://doi.org/10.3390/molecules23082020
  7. In Vitro and In Silico Studies of the Molecular Interactions of Epigallocatechin-3-O-gallate (EGCG) with Proteins That Explain the Health Benefits of Green Tea vol.23, pp.6, 2018, https://doi.org/10.3390/molecules23061295